1.12  0.4 (55.56%)		07-29 16:00
Open: 0.9 High: 1.3 Volume: 1,199,701		Pre. Close: 0.72 Low: 0.9 Market Cap: 13(M)

Short term
Mid term
Targets	6-month :	1.51	1-year :	1.77
Resists	First :	1.29	Second :	1.51
Pivot price	0.73
Supports	First :	0.87	Second :	0.61
MAs	MA(5) :	0.77	MA(20) :	0.72
	MA(100) :	0.67	MA(250) :	1.04
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	58.9	D(3) :	52.2
RSI	RSI(14): 82.6
52-week	High :	1.87	Low :	0.54

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SYBX ] has closed above the upper band by 42.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 325.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.3 - 1.31	1.31 - 1.31
Low:	0.89 - 0.89	0.89 - 0.9
Close:	1.11 - 1.12	1.12 - 1.13

Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.

Wed, 29 Jul 2026
Synlogic (SYBX) holder NEA reports 25% stake and backs Caldera merger - Stock Titan

Wed, 29 Jul 2026
Synlogic, Inc. (SYBX) holders commit 28.3% stake to Caldera merger - Stock Titan

Wed, 29 Jul 2026
Synlogic (SYBX) Merger with Caldera Therapeutics Signals Market Skepticism Amid High Price-to-Sales - GuruFocus

Wed, 29 Jul 2026
Synlogic (SYBX) plans stock merger with Caldera and $278M financing - Stock Titan

Wed, 29 Jul 2026
Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement - Business Wire

Sat, 25 Jul 2026
Synlogic, Inc. Revenue Breakdown – OTC:SYBX - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	12 (M)
Shares Float	6 (M)
Held by Insiders	16.3 (%)
Held by Institutions	35.2 (%)
Shares Short	10 (K)
Shares Short P.Month	15 (K)

EPS	-0.06
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.07
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-14.6 %
Return on Equity (ttm)	-5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	93.8 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-18.67
PEG Ratio	0
Price to Book value	1.04
Price to Sales	0
Price to Cash Flow	-3.95

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.